Abstract
Genetic variation in cytochrome enzymes is known to affect drug metabolism and influence treatment response. Recently, the rs472660 variant in CYP3A43 has been associated with olanzapine response and clearance. In this study, we investigated the impact of rs472660 and the putatively functional marker rs680055 on antipsychotic response. We genotyped the rs472660 and rs680055 single nucleotide polymorphisms (SNPs) in N = 152 schizophrenia patients of European descent collected at two sample sites who were predominately treated with second generation antipsychotics for up to 6 months. Treatment response was assessed prospectively using Brief Psychiatric Rating Scale (BPRS) scores. Statistical analysis was performed using Chi square and analysis of covariance. The rs680055 SNP was significantly associated with treatment response. Carriers of the minor allele had significantly lower BPRS scores at study end (p = 5.9 × 10–4) with 8 % of the variance being explained by rs680055 genotype. Post hoc analyses revealed that this effect was present in both samples and in both genders. The rs472660 SNP was also associated with response (p = 0.027); however, this finding was not significant after multiple test correction. This is the first evidence that the rs680055 missense mutation influences antipsychotic response. Although our finding for rs472660 was only a non-significant trend after correction, our results still support the notion that this SNP may play a role in antipsychotic response. Despite the fact that the functional role of CYP3A43 in antipsychotic metabolism is not fully understood yet, our study provides an important contribution to understanding genetic factors of antipsychotic response.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Agarwal V, Kommaddi RP, Valli K et al (2008) Drug metabolism in human brain: high levels of cytochrome P4503A43 in brain and metabolism of anti-anxiety drug alprazolam to its active metabolite. PLoS One 3:e2337
Altar CA, Hornberger J, Shewade A et al (2013) Clinical validity of cytochrome P450 metabolism and serotonin gene variants in psychiatric pharmacotherapy. Int Rev Psychiatry 25:509–533
Barnholtz-Sloan JS, Guan X, Zeigler-Johnson C et al (2011) Decision tree-based modeling of androgen pathway genes and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 20:1146–1155
Barrett JC, Fry B, Maller J et al (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21:263–265
Bigos KL, Bies RR, Pollock BG et al (2011) Genetic variation in CYP3A43 explains racial difference in olanzapine clearance. Mol Psychiatry 16:620–625
Brandl EJ, Kennedy JL, Müller DJ (2014) Pharmacogenetics of antipsychotics. Can J Psychiatry 59:76–88
Cauffiez C, Lo-Guidice JM, Chevalier D et al (2004) First report of a genetic polymorphism of the cytochrome P450 3A43 (CYP3A43) gene: identification of a loss-of-function variant. Hum Mutat 23:101
Chen CP, Chang SJ, Chern SR et al (2013) Prenatal diagnosis and molecular cytogenetic characterization of a de novo interstitial deletion of 7q (7q22.1→q31.1). Gene 521:311–315
Daly AK (2006) Significance of the minor cytochrome P450 3A isoforms. Clin Pharmacokinet 45:13–31
Domanski TL, Finta C, Halpert JR et al (2001) cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450. Mol Pharmacol 59:386–392
Dorado P, Penas-Lledo EM, Llerena A (2007) CYP2D6 polymorphism: implications for antipsychotic drug response, schizophrenia and personality traits. Pharmacogenomics 8:1597–1608
Downie D, McFadyen MC, Rooney PH et al (2005) Profiling cytochrome P450 expression in ovarian cancer: identification of prognostic markers. Clin Cancer Res 11:7369–7375
Gauderman WJ and Morrison JM (2006) A computer program for power and sample size calculations for genetic-epidemiology studies
Gellner K, Eiselt R, Hustert E et al (2001) Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene. Pharmacogenetics 11:111–121
Glykos NM, Cesareni G, Kokkinidis M (1999) Protein plasticity to the extreme: changing the topology of a 4-alpha-helical bundle with a single amino acid substitution. Structure 7:597–603
Hwang R, Souza RP, Tiwari AK et al (2011) Gene-gene interaction analyses between NMDA receptor subunit and dopamine receptor gene variants and clozapine response. Pharmacogenomics 12:277–291
Justenhoven C, Winter S, Hamann U et al (2010) The frameshift polymorphism CYP3A43_74_delA is associated with poor differentiation of breast tumors. Cancer 116:5358–5364
Lahiri DK, Nurnberger JI Jr (1991) A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res 19:5444
Leucht S, Davis JM, Engel RR, et al (2009) Definitions of response and remission in schizophrenia: recommendations for their use and their presentation. Acta Psychiatr Scand Suppl. pp 7−14
Leucht S, Rothe P, Davis JM et al (2013) Equipercentile linking of the BPRS and the PANSS. Eur Neuropsychopharmacol 23:956–959
Muller DJ, Klempan TA, De Luca V et al (2005) The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia. Neurosci Lett 379:81–89
Muller DJ, Kekin I, Kao AC et al (2013) Towards the implementation of CYP2D6 and CYP2C19 genotypes in clinical practice: update and report from a pharmacogenetic service clinic. Int Rev Psychiatry 25:554–571
Penas-Lledo EM, Llerena A (2013) CYP2D6 variation, behaviour and psychopathology: implications for pharmacogenomics-guided clinical trials. Br J Clin Pharmacol. 77(4):673–683
Pi J, Dogovski C, Pittard AJ (1998) Functional consequences of changing proline residues in the phenylalanine-specific permease of Escherichia coli. J Bacteriol 180:5515–5519
Ravindranath V, Strobel HW (2013) Cytochrome P450-mediated metabolism in brain: functional roles and their implications. Expert Opin Drug Metab Toxicol 9:551–558
Rebbeck TR, Rennert H, Walker AH et al (2008) Joint effects of inflammation and androgen metabolism on prostate cancer severity. Int J Cancer 123:1385–1389
Siemes C, Visser LE, de Jong FH et al (2010) Cytochrome P450 3A gene variation, steroid hormone serum levels and prostate cancer–The Rotterdam study. Steroids 75:1024–1032
Stingl JC, Esslinger C, Tost H et al (2012) Genetic variation in CYP2D6 impacts neural activation during cognitive tasks in humans. Neuroimage 59:2818–2823
Stone A, Ratnasinghe LD, Emerson GL et al (2005) CYP3A43 Pro(340)Ala polymorphism and prostate cancer risk in African Americans and Caucasians. Cancer Epidemiol Biomarkers Prev 14:1257–1261
Westlind A, Malmebo S, Johansson I et al (2001) Cloning and tissue distribution of a novel human cytochrome p450 of the CYP3A subfamily, CYP3A43. Biochem Biophys Res Commun 281:1349–1355
Zackrisson AL, Lindblom B, Ahlner J (2010) High frequency of occurrence of CYP2D6 gene duplication/multiduplication indicating ultrarapid metabolism among suicide cases. Clin Pharmacol Ther 88:354–359
Zeigler-Johnson C, Friebel T, Walker AH et al (2004) CYP3A4, CYP3A5, and CYP3A43 genotypes and haplotypes in the etiology and severity of prostate cancer. Cancer Res 64:8461–8467
Acknowledgments
EJB/AKT/TAL/NIC/DJM: no competing interests. HYM has received grants or is or was a consultant to: Abbott Labs, ACADIA, Alkemes, Bristol Myers Squibb, DaiNippon Sumitomo, Eli Lilly, EnVivo, Janssen, Otsuka, Pfizer, Roche, Sunovion, and BiolineRx. HYM is a shareholder of ACADIA and Glaxo Smith Kline. In the past 3 years JAL reports having received research funding or is a member of the advisory board of Allon, Alkermes Bioline, GlaxoSmithKline Intracellular Therapies, Lilly, Merck, Novartis, Pfizer, Pierre Fabre, Psychogenics, F. Hoffmann-La Roche LTD, Sepracor (Sunovion) and Targacept. JAL received no direct financial compensation or salary support for participation in these researches, consulting, or advisory board activities. JLK has been a consultant to GSK, Sanofi-Aventis, and Dainippon-Sumitomo. AKT: recipient of NARSAD 2010 young investigator award. NIC: OMHF research studentship. DJM: CIHR operating grant (Genetics of antipsychotics induced metabolic syndrome, MOP: 89853); NARSAD independent investigator award, early researcher award by the Ministry of Research and Innovation of Ontario, CIHR Michael Smith new investigator salary prize for research in Schizophrenia. JLK: recipient of a CIHR operating grant (MOP: 115097).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Brandl, E.J., Chowdhury, N.I., Tiwari, A.K. et al. Genetic variation in CYP3A43 is associated with response to antipsychotic medication. J Neural Transm 122, 29–34 (2015). https://doi.org/10.1007/s00702-014-1298-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00702-014-1298-8